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Abstract
Keratoconus (KC) is a bilateral degenerative disease of the cornea characterized by corneal bulging, stromal thinning, and
scarring. The etiology of the disease is unknown. In this study, we identified a new biomarker for KC that is present in vivo
and in vitro. In vivo, tear samples were collected from age-matched controls with no eye disease (n=36) and KC diagnosed
subjects (n=17). Samples were processed for proteomics using LC-MS/MS. In vitro, cells were isolated from controls (Human
Corneal Fibroblasts-HCF) and KC subjects (Human Keratoconus Cells-HKC) and stimulated with a Vitamin C (VitC) derivative
for 4 weeks, and with one of the three transforming growth factor-beta (TGF-b) isoforms. Samples were analyzed using real-
time PCR and Western Blots. By using proteomics analysis, the Gross cystic disease fluid protein-15 (GCDFP-15) or prolactin-
inducible protein (PIP) was found to be the best independent biomarker able to discriminate between KC and controls. The
intensity of GCDFP-15/PIP was significantly higher in healthy subjects compared to KC-diagnosed. Similar findings were
seen in vitro, using a 3D culture model. All three TGF-b isoforms significantly down-regulated the expression of GCDFP-15/
PIP. Zinc-alpha-2-glycoprotein (AZGP1), a protein that binds to PIP, was identified by proteomics and cell culture to be
highly regulated. In this study by different complementary techniques we confirmed the potential role of GCDFP-15/PIP as a
novel biomarker for KC disease. It is likely that exploring the GCDFP-15/PIP-AZGP1 interactions will help better understand
the mechanism of KC disease.
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Introduction
Keratoconus (KC) is an ectatic eye disease associated with
structural abnormalities in the cornea [1]. KC is characterized by
a central or paracentral stroma thinning, corneal bulging, and
scarring [1–3]. Other characteristics include the appearance of
Fleischer’s ring, interruptions in Bowman’s layer, decreased
keratocyte density, and severe changes in collagen gross organi-
zation [4]. KC typically appears in teens and progresses until the
third or fourth decade of life [5]. The severity of the disease and
how this is reached varies considerably between individuals.
Ultimately, vision quality is compromised and corneal transplan-
tation is required in severe cases.
The pathophysiology of KC is still unknown and early
asymptomatic onset of the disease progresses freely [1,6,7]. Once
KC has reached a certain level diagnosis can be made by corneal
imaging techniques either by documentation of an irregular
increase in the refractive power of the anterior cornea or a
localized thinning of the corneal stroma, but most often a
combination of these finding [7,8]. Individuals diagnosed with
early KC are regularly prescribed with contact lenses, not for
treatment but to maintain good vision [7]. The progression of
keratoconus can in most of the milder cases be halted by corneal
cross-linking [9–11], which is used in most countries, although
FDA-approval is still ongoing in the US. Advanced stages require
corneal transplantation.
Despite significant efforts, a sensitive and specific biomarker for
keratoconus has not been identified. Early identification of subjects
prone to develop keratoconus would be useful in identifying
subjects, which should be followed with detailed corneal imaging,
as corneal cross-linking recently has been documented to halt
disease progression in keratoconus. A marker would also be very
useful in screening patients seeking corneal refractive surgery.
After laser surgical procedures, a small number of patients are
known to develop ‘‘iatrogenic ectasia’’ which is very similar to
naturally occurring keratoconus. In this study we propose a
potential new biomarker for the identification of KC. Gross cystic
disease fluid protein-15(GCDFP-15) also known as prolactin-
inducible protein (PIP) is a secretory glycoprotein of 14 Kda [12]
which others have found expression of in the proteome of human
tear fluids [13]. Quality of tear fluids are key in maintenance of
healthy cornea structure and the vast majority on KC studies are
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cases.
We have recently reported a 3D culture system for studying
human keratoconus cells (HKC) [7,14]. We have reported findings
that are in agreement with what is seen in vivo, such as increased
oxidative stress levels in HKCs when compared to normal human
corneal fibroblasts (HCF) [11]. Here we collected human tear
samples and using proteomics analysis we identified PIP as a
potential biomarker for KC disease. In order to validate our
findings and integrate our in vivo data with the in vitro model we
used our 3D in vitro culture model. The regulation of PIP was
validated using real time PCR and western blot analysis. To the
authors knowledge this is one of the first studies to identify a
potential biomarker for KC disease that is regulated similarly both
in vivo and in vitro.
To reinforce our findings, Zinc-alpha-2-glycoprotein (AZGP1),
a gene that is known to stimulate breakdown of lipids (lipolysis)
[15,16] and bind to PIP was also found to be significantly
regulated both in vivo and in vitro. This indicates that the
interplay between the two proteins (PIP-AZGP1) might provide
clues to KC pathogenesis.
Further understanding of the mechanism of how PIP is
regulated is clearly needed. We present evidences that one of the
main growth factors involved in corneal wound healing as well as
KC disease; transforming growth factor-b (TGF-b), can signifi-
cantly regulate PIP and its expression. This could potentially have
major implications in the prevention and prognosis of KC disease.
Methods
Subject recruitment
36 patients referred to the Department of Ophthalmology,
Aarhus University Hospital for keratoconus was asked to provide a
tear sample for testing. All patients underwent a standard clinical
examination including refraction, measurement of best corrected
visual acuity, slit-lamp examination, and Pentacam HR Scheimp-
flug tomography. 17 patients referred for refractive surgery for
myopia underwent similar examination and served as control
group. Tears were collected in capillary glass tubes from the lateral
tear meniscus. Care was taken not to stimulate tear secretion
during collection.
Ethics
Tear collection was considered part of the highly specialized
clinical and para-clinical evaluation of patients referred to the
department. Initially, tear samples were collected for methods
development. The Regional Ethics Committee for the Central
Region of Denmark approved this study and written consent was
obtained from the study participants. The approval reference
number is: 1-10-72-77-14. The study met the tenets of the
Declaration of Helsinki. Tear samples were anonymized before
analysis.
Proteomics-tandem mass spectrometry
As previously reported by us and others, all tear samples were
analyzed by microcapillary liquid chromatography-tandem mass
spectrometry (LC-MS/MS) [11,17,18] using the EASY-nLC
nanoflow HPLC (Thermo Fisher Scientific; Waltham, MA) with
a7 5mm inner diameter 6 15 cm length C18 capillary column
coupled to a hybrid LTQ Orbitrap XL-ETD mass spectrometer
(Thermo Fisher Scientific). Label-free quantification was used to
quantify and determine the differential expression levels of
proteins between samples. The high-resolution power facilitated
the extraction of peptide signals on the MS level, thus uncoupling
the quantification from the identification process [11,17,18].
Proteins that were not expressed in the majority of the samples,
were excluded from our quantification.
Isolation and primary cells
HCFs were isolated from human corneas from healthy patients
without ocular disease. All samples were obtained from NDRI
(National Disease Research Interchange; Philadelphia, PA; http://
www.ndri.org/) as previously described [11,14,19]. HKCs were
isolated from human corneas from anonymized patients undergo-
ing corneal transplantation for keratoconus at Aarhus University
Hospital, Aarhus, Denmark. The research adhered to the tenets of
the Declaration of Helsinki. The tissue was obtained and used for
scientific purpose and ethical issues have been handled according
to Danish healthcare law (research in anonymized biological
material which is normally discarded), and after guidance from the
local ethical committee (The Regional Ethics Committee for the
Central Region of Denmark), and in accordance with the
Declaration of Helsinki.
As previously described [19] the corneal epithelium and
endothelium were removed from the stroma by scraping with a
razor blade. The stromal tissues were cut into small pieces of size
, 262 mm and placed into T25 culture flaks. Explants were
allowed to adhere to the bottom of the flask at 37uC for about 30
minutes and Eagle’s Minimum Essential Medium (EMEM:
ATCC: Manassas, VA) containing 10% fetal bovine serum
(FBS: Atlantic Biological’s; Lawrenceville, CA) and 1% Antibiotic
(Gibco Antibiotic-Antimycotic, Life technologies) was added
carefully without disturbing the implants. Further, the cells were
passaged into T75 culture flasks upon 100% confluence after 1–2
weeks of cultivation at 37uC, 5%CO2.
Culture and assembly of ECM
Both HCFs and HKCs cells were cultured on 6-well tissue
culture plates and processed for q RT- PCR and western blot
analysis [19,20]. 1610
6 cells/well of these cells was seeded and
cultured in EMEM 10%FBS medium stimulated with 0.5 mM 2-
O-a-D-Glucopyranosyl-L-Ascorbic Acid (Vit C, American Cus-
tom Chemicals Corporation, San Diego, CA). Cells were further
stimulated with one of the three TGF-b isoforms: TGF-b1 (T1),
TGF-b2 (T2) and TGF-b3 (T3). All isoforms were used at 0.1 ng/
mL concentration as previously optimized [19–21]. The cultures
were grown for four weeks before further processing. Cultures
without any growth factors served as the controls (C). Fresh media
was supplied to the cultures every other day for the whole duration
of the experiment.
Real Time PCR
For evaluation of the m RNA expression, q RT-PCR was done
on all samples as previously described [19,21–23]. Briefly, total
RNA extraction was carried out using Ambion RNA mini
extraction kit (Ambion TRIzol Plus RNA Purification Kit: Life
technologies, Carlsbad, CA). The cDNA synthesis was followed
using a SuperScript III First-Strand Synthesis SuperMix (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s protocol.
TaqMan gene expression assay (Applied Biosystems, Foster City)
GAPDH (Hs99999905_m1) and 18S (Hs99999901_s1) was used
as control and PIP (Hs00160082_m1) and AZGPI
(Hs00426651_m1) as study probe. The reaction was set up using
10 ng of cDNA in a 20-ml reaction containing our probe of interest
and Taqman FaSt Advanced Master Mix (Applied Biosystems,
Life technologies, Foster city, CA). StepOnePlus real-time PCR
system (Life Technologies, Foster city, CA) was used for
amplification of the sample using standard manufacturer’s
Prolactin-Inducible Protein: Keratoconus Biomarker
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analysis. All samples and probes were repeated at least three times.
Western blot
Cell lysates for HCFs and HKCs were prepared for western blot
analysis, as previously described [21,24]. Briefly, bradford assay
(Thermo scientific, IL, USA) [21] was carried for determining the
protein concentration and purity. Samples were mixed with
loading buffer and equal amounts of protein were loaded on
readymade 4–20% Tris-Glycine gel (Novex, Life technologies,
Carlsbad, CA) for gel electrophoresis. Proteins were transferred on
to a nitrocellulose membrane (Novex, Nitrocellulose membrane
filter par sandwich, Life Technologies, Carlsbad, CA). Thereafter
the membranes were incubated in two different blocking solutions
(5% milk in TBST; Thermo scientific, IL, USA) and (5% BSA in
TBST) as per the manufacturer’s antibody specification protocol;
for 1 hour and incubated overnight at 4uC with primary antibody
(Rabbit Monoclonal Anti-GCDFP 15 and Rabbit polyclonal Anti-
Zinc Alpha 2 Glycoprotein, Abcam, Cambridge, MA) at 1:1000
dilutions. Thereafter membranes were washed and incubated with
a secondary antibody (Alexa Flour 568 Donkey Anti-Rabbit, IgG
(H+L), Abcam) with 1:2000 dilutions for 1 hour. The binding of
antibodies to the membrane was detected with Kodak imaging
system. Result were analyzed by normalizing the value to that of
the house keeping antibody GAPDH (Abcam, Cambridge, MA)
expression and the fold expression was plotted.
Statistical Analysis
Data analysis for the sample sets, n=3 was done by one -way
ANOVA using Graph Pad Prism 6 software. Where P value (P,
0.05) was considered to be statistically significant.
Results
Pentacam
As shown in Table 1 the mean age for healthy individuals was
33 (range from 18 to 47 years). For Keratoconus individuals the
average age was 30 (range 21 to 59 years). There were no
statistically significant differences in age between the study groups.
All individuals participating in the study were examined using the
Pentacam. A variety of values were collected. The mean corneal
thickness for the control group was 501.2, and for the keratoconus
group was recorded as 466 (Table 1). Maximum keratometric
(Kmax) average value for the controls was 46.9, and the
keratoconus group average value was 53.9 (Table 1).
Proteomics analysis
All tear samples were analyzed by microcapillary liquid
chromatography-tandem mass spectrometry (LC-MS/MS). Our
study confirmed the findings of previous studies with some of the
most common proteins regulated in KC tear samples reported in
table 2. Lipophilin-A, Immunoglobulin J Chain, Cystatin-S, and
Lactotransferrin were all significantly down regulated (p,0.0001)
in KC tear samples. AZGP1, a closely related protein to PIP was
slightly up regulated in KC but did not reach significance
(p=0.18).
mRNA expression
We quantified the mRNA expression levels of both PIP and
AZGPI in the HCFs and HKCs. Figure 1 shows the PIP
expression under four different conditions; Control, TGF-b1,
TGF-b2, and TGF-b3. Upon treatment with the three TGF-b
isoforms, levels of PIP were significantly lower (p,0.0001) for both
cell types (Figure 1A and 1B). TGF-b2 and TGF-b3 almost shut
down expression of PIP in HKCs.
The mRNA expression of AZGPI was also tested due to the
interplay between the two genes. Figure 2 shows expression of
AZGPI in HCFs (Figure 2A) and HKCs (Figure 2B). TGF-b1 led
to significant up regulation of AZGPI in HCFs (Figure 2A; p,
0.0005) while no change was noted in HKCs. This was opposite to
the PIP regulation with TGF-b1 (Figure 1). TGF-b3 on the other
hand down regulated AZGPI expression in HCFs. Again no effect
was noted in HKCs. Interestingly, when cells were stimulated with
TGF-b2 no expression was found in HCFs, where HKCs
expression was significantly down regulated when compared to
Controls (Figure 2B; p,0.05).
Protein expression
We examined the protein expression of both PIP and AZGPI
for both cell types. Figures 3 and 4 shows the fold enhancement
quantified data obtained for HCFs and HKCs respectively. Values
were normalized to the expression of the controls of the respective
cell type. Opposite to the mRNA levels, HCFs PIP protein
expression was up regulated upon all TGFb treatment (Figure 3A)
however none of them reached significant values (p=0.2457).
However, HKCs showed identical regulation at the protein level
(Figure 3B) as with the mRNA level (Figure 1B), where PIP was
significantly down regulated upon TGFb stimulation. All isoforms
resulted in PIP protein down regulation compared to Controls
(TGFb-1: p,0.05, TGFb2: p,0.05, and TGFb3: p,0.001). As
with the mRNA expression, PIP protein levels were lower with
TGFb3 treatment (Figure 3B). Of note here, HCF’s PIP protein
expression was seen at 17 kDa protein whereas in HKC’s at
37 kDa. This higher kDa protein expression indicates the presence
of a glycosylated version of the protein.
The expression pattern for AZGPI in HCFs was rather similar
to that of HKCs (Figure 4A). In HCFs all three TGFb isoforms
resulted in significant down regulation (p,0.0001) of AZGPI
protein expression with TGFb1 showing the lowest of the three
when compared to the controls (Figure 4A). This is in agreement
with our mRNA levels regulation. In the case of HKCs, treatment
with TGFb1 and TGFb2 isoforms showed identical AZGPI
protein expression, whereas treatment with TGFb3 greatly
resulted in decreased protein expression (Figure 4B; p,0.05).
Table 1. Pentacam data collected from participating subjects.
Age (years) Ct min (um) Kmax (D)
Control 3368.58 501.268.94 46.964.69
Keratoconus 30610.58 46664.77 53.967.79
Summary of the mean ages, corneal thickness (Ct min) and maximum keratometric (Kmax) values for: Controls and Keratoconus. Mean age for Control was 33 and for KC
the average age was 30. No statistically significant differences were found. The Ct min for Controls was 501.2 and KC was recorded as 466. There was a statistically
difference between the two groups (p,0.05). Kmax average value for the controls was 46.9 and the KC average value was 53.9.
doi:10.1371/journal.pone.0113310.t001
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similarly regulated upon TGFb stimulation; especially with
TGFb3. These results confirm the prognostic properties of TGFb3
during diseased condition. Similar to what was seen with PIP,
HCF’s expression of AZGP1 was seen at 26 kDa where HKCs at
37 kDa.
Discussion
Keratoconus is a progressive degenerative disease and a major
clinical problem worldwide [11]. The disease can progress rapidly
starting at puberty [19] and can lead to blindness if not treated.
Early clinical detection of this disease is a challenge and usually
signs and symptoms are similar to those seen in severe
astigmatism. One of the major limitations for the understanding
of the disease is the unavailability of an animal model as well as an
in vitro model. In 2012 [19] we proposed a novel 3D culture
system for studying HKC in vitro. We have characterized and
continue to develop this model in order to dissect the mechanisms
of KC. Clearly, substantial work still remains in order to identify
the exact etiology for the onset of disease.
KC studies have suggested that genetic, environmental, and
molecular factors might be playing an important role. All of these
studies have indicated that specific biomarkers for early detection
of the disease, which would allow early treatment, are missing.
Over the last decade, studies have concentrated on tear fluids for
identification of such a biomarker. The rationale behind thes
studies have been that the quality of tear fluids are considered to
be the key in maintenance of healthy cornea structure [25]. Some
studies have suggested that the imbalance in presence of cytokines,
enzymes, enzyme inhibitors and other mediators in the tear fluid
might be playing an important role in the development of the
disease [26]. Others have shown evidence of oxidative stress [11]
with altered antioxidant enzymes [27–30], accumulated bypro-
ducts from lipid peroxidation, nitric oxide pathways [31,32] and
damaged mitochondrial membrane potential [33,34]. Biomechan-
ics and collagen structure has also been investigated by scientists. A
variety of techniques have been used in order to compare normal
and keratoconus corneal stroma structure. Multiple groups have
used X-ray scattering and scanning electron microscopy [35–38]
to map the collagen orientation and fibrillar mass in keratoconus
corneal buttons. Meek and co-authors, in a more advanced
approach, reported the relationship between corneal shape and
thickness in keratoconus samples using combination of videoker-
atography and X-ray scattering by Hayes et al [39].
In this study, using both in vivo and in vitro systems, we report
GCDFP-15/PIP as a potential novel biomarker possessing
predictive and prognostic effect for KC. GCDFP-15/PIP is a
secretory acinar protein of 14–17 kDa molecular weight, which is
normally secreted in various body fluids [12,40–43], and has
already been demonstrated to be a novel biomarker in cancer and
several other diseases [13,22–26]. These studies have reported
expression of this protein at various levels with variable levels of
glycosylation.
In our in vivo proteomics analysis we found proteins whose
levels are altered in KC compared to healthy individuals with no
Table 2. Selected proteins regulated in tears. * indicates statistical significance.
Normal Keratoconus P value
Lipophilin-A 3.44E+0866.15E+07 2.48E+0461.82E+03 P,0.0001*
Immunoglobulin J Chain 4.85E+0861.69E+08 2.10E+0461.83E+03 P,0.0001*
Zinc-alpha-2-glycoprotein (AZGP1) 2.86E+0861.06E+08 5.82E+0861.76E+08 P=0.18
Cystatin-S 6.50E+0862.30E+08 1.90E+0461.13E+03 P,0.0001*
Prolactin-inducible protein (PIP) 1.45E+0964.83E+08 2.63E+0463.34E+03 P,0.0001*
Lactotransferrin 1.40E+1064.30E+09 2.12E+0469.43E+02 P,0.0001*
Secreted frizzled-related protein 1 1.28E+0665.26E+05 2.87E+0665.27E+05 P=0.076
Summary of the most common proteins regulated in KC tear samples. Lipophilin-A, Immunoglobulin J Chain, Cystatin-S, and Lactotransferrin were all significantly down
regulated (p,0.0001) in KC tear samples. No significant changes in the levels of Secreted frizzled-related protein 1 and AZGPI (p,0.076 and p=0.18 respectively) was
found. PIP was significantly down regulated (p,0.0001) in KCs.
doi:10.1371/journal.pone.0113310.t002
Figure 1. PIP quantified mRNA expression for A) HCF and B) HKC cell types. Four conditions were tested: Control, TGF-b1, TGF-b2, and TGF-
b3. All three TGF-b isoforms resulted in significant down regulation of PIP for both cell types. All error bars represent standard error (SEM) of n=3.
doi:10.1371/journal.pone.0113310.g001
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globulin J chain, Cystatin S, Lactotransferin and secreted frizzled-
related protein 1. Our proteomics data also showed regulation of
PIP. PIP is closely related to AZGPI protein, which in our group of
patients was not significantly altered. However, the binding
relationship PIP at a similar region encouraged us to consider it
further. It has been reported that AZGPI and PIP forms a complex
[15] in some body fluids and they localize in close vicinity in the
same chromosome [44–46] and are both regulated by androgens
[15]. AZGPI which is also a glycoprotein has been found to
stimulate lipolysis [28] because of its ability to play many
important function in the human body it has been considered as
a potential bio marker for various studies especially for cancer
related research [22,28]. AZGPI has been reported to be a protein
of 35–44 kDa.
We confirmed the importance of PIP and AZGPI using our 3D
in vitro model. Our previous studies on HCKs and HCFs using
this model have been concentrated on the three TGF-b isoforms
and their significance in corneal fibrosis effects and elevated ECM
production [19–22,47–49]. We have shown that TGF b3 is anti-
fibrotic in HCFs and promotes ECM assembly similar to that seen
in vivo. We therefore investigated their role on regulating PIP and
AZGPI in vitro, and determined a higher m RNA for GCDFP-
15/PIP in HCFs in comparison to HKCs. Upon TGF-b3
treatment, the expression pattern decreased in comparison to the
HCFs. The m RNA expression for the AZGPI genes showed a
similar pattern of expression to that of the PIP for TGF-b isoform
treated samples. Interestingly, no m RNA expression was seen
with TGF-b2 treatment in HCFs when compared to HKCs. This
suggests the possible masking or inhibition effect of the growth
factor on the gene expression. In order to further investigate this
and evaluate the PIP as a biomarker we performed a western blot
analysis on all our samples.
Both HCFs and HKCs showed a sequentially increased level of
protein expression with the treatment of TGF-b isoforms when
compared to the controls. Interestingly, HCF’s GCDFP-15/PIP
Figure 2. AZGPI quantified mRNA expression for A) HCF and B) HKC cell types. Four conditions were tested: Control, TGF-b1, TGF-b2, and
TGF-b3. TGF-b1 led to an increase of AZGPI in HCFs where no effect was seen in HKCs. When cells were stimulated with TGF-b2 no expression was
found in HCFs, where HKCs expression was significantly down regulated when compared to the Controls. Upon TGF-b3 treatment AZGPI expression
was significantly down regulated for HCFs while it remained unchanged for HKCs. All error bars represent standard error (SEM) of n=3.
doi:10.1371/journal.pone.0113310.g002
Figure 3. PIP quantified protein expression for A) HCF and B) HKC cell types. Four conditions were tested: Control, TGF-b1, TGF-b2, and
TGF-b3. HCFs expression was increased upon TGFb treatments however none of them reached significance. HKCs showed significant down
regulation upon all TGFb treatments. TGFb3 showed the lowest PIP protein levels compared to all other conditions. HKCs PIP protein levels were
consistently lower under all conditions when compared to HCFs. Note: HCF’s PIP expression was seen at 17 kDa protein whereas in HKC’s at 37 kDa.
All error bars represent standard error (SEM) of n=3.
doi:10.1371/journal.pone.0113310.g003
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expression was observed. The higher kDa protein expression
suggests the presence of a glycosylated version of the protein
[12,15,50]. Clinically this would suggest that several mediators
secreted in KC tears like cytokines and enzymatic inhibitors [26]
bind to the PIP protein and result in significant drift to a higher
molecular weight. The exact biological function of PIP is not clear,
however, it has been reported to bind many proteins like
fibrinogen, actin, keratin myosin, and CD34 molecule of T cells
[12,40]. Predicting the reason for the higher molecular weight
protein expression at this stage is rather challenging and future
analysis of this protein will be needed to provide a better picture of
the exact specificity and nature of the protein.
Overall, it is evident from our data that both genes were
significantly decreased by TGF-b3 treatment in HKCs compared
to the HCFs, This indicates PIP/AZGPI can certainly be a
prognostic indicator during the pathogenesis of the disease.
AZGPI has been reported to regulate lipid metabolism, induce
lipolysis, and down regulation in obese patients [51]. This provides
strong evidence that it is strongly associated with body metabolism
and secretion of different amounts of metabolites might be directly
or indirectly engaged in deciding the expression pattern of the
genes. This would agree with our previous findings and the role of
TGF-b3 in HKCs [11].
GCDFP-15/PIP and AZGPI both are present in the same
chromosome and both inaccessible from the N-terminal region
due to the presence of pyroglutamine [15]. This gives them almost
identical structure and nature. Furthermore, they both bound to
the nucleus and the membrane region and have been identified to
possess a remarkable binding pattern to each other [43]. In
addition, both are involved in cell cycle regulation, having effect
on proliferation and inhibition of cells and they are also considered
to be present in the same overlapping signaling pathways [52].
Further studies are clearly needed in order to understand their
role in KC as well as their relationship to TGF-b isoforms.
Previous studies have reported activation of PIP and AZGPI via
cAMP signaling by ERK-dependent pathway. Therefore, we
predict that due to the same binding zones and strong affinity for
each other, the possible activation pathway for both the genes
could be STAT5. STAT which is a latent cytoplasmic protein
activated upon receptor stimulation is found to be mediated by
protein tyrosine kinases. It has been reported after phosphoryla-
tion with tyrosine the STAT pathway acquires binding ability and
translocate to the nucleus by binding to the specific promoter
elements and controls the expression of the target genes. Their
involvement in various pathological conditions has been well
established [53–55].
In conclusion, it can be strongly stated that both GCDFP-15/
PIP and AZGPI hold great promise as novel prognostic and
predictive biomarkers for KC and can provide various clues at
various levels of disease progression. This is the initial report of
these two genes as biomarkers for KC. Further extensive research
of the possible pathways and gene expression patterns of these
markers might lead to determining the pathological treatment for
KC.
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